Deferasirox is an iron chelator used to treat chronic iron overload caused by blood transfusions. Also used in patients with non-transfusion-dependent thalassemia syndromes, and in patients with elevated liver iron concentration and serum ferritin.
- Mechanism
- Curator reviewed
Two molecules of deferasirox are capable of binding to 1 atom of iron. Deferasirox works in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys.
- Primary indication
- For the treatment of chronic iron overload due to blood transfusions (transfusional hemosiderosis) in patients 2 years of age and older.Curator reviewed · 2 structured indications
- Formula / weight
- C21H15N3O4 · 373.3615 g/mol (avg)
- First approval
- Canada, 2006 · United States, 2005 · European Union, 2016
- Code names
- ICL-670 · ICL-670A
- Brand names
Resolves to
BOFQWVMAQOTZIW-UHFFFAOYSA-NSMILESOC(=O)C1=CC=C(C=C1)N1N=C(N=C1C1=CC=CC=C1O)C1=CC=CC=C1OWhat you can answer from here — as of September 23, 2026
Which other approved drugs treat the same conditions as Deferasirox, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account